Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B

by

in

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday.

The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500 also rose, gaining, 0.30% to 5,041.87.

Check This Out: Caterpillar, Marathon Petroleum And More On CNBC’s ‘Final Trades’

 

Leading and Lagging Sectors

 

Energy shares rose by 1.1% on Monday.

In trading on Monday, health care shares fell by 0.1%.

 

Top Headline

 

Gilead Sciences Inc (NASDAQ: GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ: CBAY) for $32.50 per share in cash or a total equity value of $4.3 billion.

The addition of CymaBay’s investigational lead product candidate, seladelpar for primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio.

 

Equities Trading UP

 

Beamr Imaging Ltd. (NASDAQ: BMR) shares shot up 975% to $22.70 after the company announced it will present its joint …

Full story available on Benzinga.com